{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:24Z","timestamp":1793968284900,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101158055"],"award-info":[{"award-number":["101158055"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030886","name":"Zimin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024250","name":"Israel Innovation Authority","doi-asserted-by":"publisher","award":["73182"],"award-info":[{"award-number":["73182"]}],"id":[{"id":"10.13039\/501100024250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102981","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:29:26Z","timestamp":1786465766000},"page":"102981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early detection of chimeric antigen receptor-T-associated neurotoxicity via cytokine monitoring in serum"],"prefix":"10.1016","volume":"28","author":[{"given":"Amit","family":"Parizat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-6913","authenticated-orcid":false,"given":"Onit","family":"Alalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7773-7152","authenticated-orcid":false,"given":"Danielle","family":"Sapir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivin","family":"Shibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofrat Beyar","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Shechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102981_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2026.102981_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell\u2013Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102981_bib0003","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2026.102981_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102981_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2026.102981_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2026.102981_bib0007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102981_bib0008","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.jcyt.2026.102981_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102981_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2026.102981_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.jcyt.2026.102981_bib0012","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102981_bib0013","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/cancers16193339","article-title":"Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies","volume":"16","author":"Ploch","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2026.102981_bib0014","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","article-title":"Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy","volume":"206","author":"Tedesco","year":"2021","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.jcyt.2026.102981_bib0015","article-title":"Cytokines: From Clinical Significance to Quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jcyt.2026.102981_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2008.10.002","article-title":"Validation and comparison of two multiplex technologies, Luminex\u00ae and Mesoscale Discovery, for human cytokine profiling","volume":"340","author":"Chowdhury","year":"2009","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/j.jcyt.2026.102981_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/labmed\/lmae064","article-title":"Analytical evaluation of the automated interleukin-6 assay on the Roche cobas e602 analyzer","volume":"56","author":"Gant Kanegusuku","year":"2025","journal-title":"Laboratory Medicine"},{"key":"10.1016\/j.jcyt.2026.102981_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/anie.201913924","article-title":"Advances in Optical Single-Molecule Detection: En Route to Supersensitive Bioaffinity Assays","volume":"59","author":"Farka","year":"2020","journal-title":"Angewandte Chemie - International Edition"},{"key":"10.1016\/j.jcyt.2026.102981_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115206","article-title":"Lateral flow assays for detection of disease biomarkers","volume":"225","author":"Gumus","year":"2023","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jcyt.2026.102981_bib0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1373\/clinchem.2012.200360","article-title":"Lateral Flow Assay with Near-Infrared Dye for Multiplex Detection","volume":"59","author":"Swanson","year":"2013","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.jcyt.2026.102981_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1250358","article-title":"Efficacy of a paper-based interleukin-6 test strip combined with a spectrum-based optical reader for sequential monitoring and early recognition of respiratory failure in elderly pneumonia\u2014a pilot study","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcyt.2026.102981_bib0022","series-title":"ELISA: Methods and Protocols","first-page":"141","article-title":"Lateral Flow Microarray-Based ELISA for Cytokines","author":"Matson","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102981_bib0023","article-title":"Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson\u2019s disease","volume":"2","author":"Lasseter","year":"2020","journal-title":"Cytokine: X"},{"key":"10.1016\/j.jcyt.2026.102981_bib0024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cyto.2018.05.032","article-title":"A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence?","volume":"111","author":"Casaletto","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.jcyt.2026.102981_bib0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","article-title":"Akaike\u2019s Information Criterion in Generalized Estimating Equations","volume":"57","author":"Pan","year":"2001","journal-title":"Biometrics"},{"key":"10.1016\/j.jcyt.2026.102981_bib0026","first-page":"1065","article-title":"Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"10.1016\/j.jcyt.2026.102981_bib0027","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102981_bib0028","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.jcyt.2026.102981_bib0029","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102981_bib0030","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102981_bib0031","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell\u2013associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Advances"},{"key":"10.1016\/j.jcyt.2026.102981_bib0032","series-title":"Ultralytics YOLO11 [computer software]","author":"Jocher","year":"2024"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:23:21Z","timestamp":1793967801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926009424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1465324926009424"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102981","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early detection of chimeric antigen receptor-T-associated neurotoxicity via cytokine monitoring in serum","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102981"}}